Study reveals no neuroinflammation in long COVID patients with neuropsychiatric symptoms

In a JAMA Network Open study, researchers found no evidence of neuroinflammation or blood-brain barrier dysfunction in cerebrospinal fluid markers of individuals with post-COVID-19 condition and neuropsychiatric symptoms compared to controls. The study, which assessed cytokines, chemokines, and neuroinflammation markers, suggests that persistent central nervous system immune activation may not be the primary driver of neurological long COVID symptoms.

FSD Pharma names new CEO

Unbuzzd supports the function of the liver and brain in rapidly alleviating the effects of alcohol intake. Credit: Louis Reed on Unsplash. FSD Pharma has named

Read More »